25 XP   0   0   10

Bioteque
Buy, Hold or Sell?

Let's analyse Bioteq together

PenkeI guess you are interested in Bioteque. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Bioteque. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Bioteque

I send you an email if I find something interesting about Bioteque.

Quick analysis of Bioteq (30 sec.)










What can you expect buying and holding a share of Bioteq? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
71.4%

What is your share worth?

Current worth
NT$46.03
Expected worth in 1 year
NT$48.32
How sure are you?
95.2%

+ What do you gain per year?

Total Gains per Share
NT$2.28
Return On Investment
1.8%

For what price can you sell your share?

Current Price per Share
NT$124.00
Expected price per share
NT$115.50 - NT$127.50
How sure are you?
50%

1. Valuation of Bioteq (5 min.)




Live pricePrice per Share (EOD)

NT$124.00

Intrinsic Value Per Share

NT$92.72 - NT$110.79

Total Value Per Share

NT$138.76 - NT$156.82

2. Growth of Bioteq (5 min.)




Is Bioteq growing?

Current yearPrevious yearGrowGrow %
How rich?$98.2m$87.5m$5m5.5%

How much money is Bioteq making?

Current yearPrevious yearGrowGrow %
Making money$3.4m$3.8m-$315.6k-9.1%
Net Profit Margin23.2%24.6%--

How much money comes from the company's main activities?

3. Financial Health of Bioteq (5 min.)




4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)




  Industry Rankings (Medical Instruments & Supplies)  


Richest
#104 / 171

Most Revenue
#119 / 171

Most Profit
#86 / 171

What can you expect buying and holding a share of Bioteq? (5 min.)

Welcome investor! Bioteq's management wants to use your money to grow the business. In return you get a share of Bioteq.

What can you expect buying and holding a share of Bioteq?

First you should know what it really means to hold a share of Bioteq. And how you can make/lose money.

Speculation

The Price per Share of Bioteq is NT$124.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bioteq.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bioteq, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$46.03. Based on the TTM, the Book Value Change Per Share is NT$0.57 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.83 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bioteq.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps0.050.0%0.050.0%0.050.0%0.050.0%0.050.0%
Usd Book Value Change Per Share0.040.0%0.020.0%0.030.0%0.020.0%0.070.1%
Usd Dividend Per Share0.000.0%0.000.0%0.100.1%0.090.1%0.090.1%
Usd Total Gains Per Share0.040.0%0.020.0%0.130.1%0.110.1%0.160.1%
Usd Price Per Share3.39-3.41-3.43-3.67-3.63-
Price to Earnings Ratio18.12-17.44-15.66-18.03-17.85-
Price-to-Total Gains Ratio79.48-39.42-42.34-43.39-41.45-
Price to Book Ratio2.39-2.56-2.72-3.08-3.06-
Price-to-Total Gains Ratio79.48-39.42-42.34-43.39-41.45-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.8192
Number of shares261
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.09
Usd Book Value Change Per Share0.020.02
Usd Total Gains Per Share0.020.11
Gains per Quarter (261 shares)4.5928.39
Gains per Year (261 shares)18.34113.58
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101889320104
20372618741218
30554428061332
40736237381446
509280466102560
6011098560122674
70128116653142788
80147134746163902
901651528391831016
1001831709332031130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%21.00.00.0100.0%21.00.00.0100.0%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%16.05.00.076.2%16.05.00.076.2%
Dividend per Share0.00.04.00.0%7.00.05.058.3%14.00.06.070.0%15.00.06.071.4%15.00.06.071.4%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%20.01.00.095.2%20.01.00.095.2%

Fundamentals of Bioteq

About Bioteque

Bioteque Corporation manufactures and sells medical devices in Asia, South America, North America, and internationally. The company provides medical disposables for use in hemodialysis access, endovascular treatment, and other fields. It also offers dialysis products, including hemodialysis bloodlines, A.V.F. needles, and hemodialysis cathers; interventional radiology products, such as pigtail drainage catheter sets, introducer sets, connecting tubes, drainage bags, and radiopaque dilators; urology products comprising ureteral stent sets and urine collection bags; and IV administration products, such as PVC IV infusion bags, PVC bags, and twist-off ports. In addition, the company provides respiratory care products, such as closed suction catheters and endotracheal tubes; vascular access products comprising angiographic catheters, PTA balloon dilatation catheters, sheath introducers, guidewires, high pressure connecting tubes, PTCA balloon dilatation catheter-rapid exchange products, manifolds, and Y connectors; and medical components, including dialyzer connectors and caps, recirculating connectors with cap, rotating luer lock connectors, pump and T connectors, female luers, injection sites, luer lock and chamber caps, drip chambers, filters, clamps, pressure pillows, safeline HDF components, chamber assembly, and transducer protectors, as well as medical masks. Bioteque Corporation was incorporated in 1991 and is headquartered in Taipei, Taiwan.

Fundamental data was last updated by Penke on 2024-04-16 21:52:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Bioteque.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Bioteq earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Bioteq to the Medical Instruments & Supplies industry mean.
  • A Net Profit Margin of 20.3% means that NT$0.20 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bioteque:

  • The MRQ is 20.3%. The company is making a huge profit. +2
  • The TTM is 23.2%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ20.3%TTM23.2%-3.0%
TTM23.2%YOY24.6%-1.4%
TTM23.2%5Y24.3%-1.0%
5Y24.3%10Y24.4%-0.2%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ20.3%6.3%+14.0%
TTM23.2%6.5%+16.7%
YOY24.6%8.2%+16.4%
5Y24.3%7.3%+17.0%
10Y24.4%7.6%+16.8%
1.1.2. Return on Assets

Shows how efficient Bioteq is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bioteq to the Medical Instruments & Supplies industry mean.
  • 2.3% Return on Assets means that Bioteq generated NT$0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bioteque:

  • The MRQ is 2.3%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.3%TTM2.5%-0.2%
TTM2.5%YOY2.9%-0.4%
TTM2.5%5Y3.2%-0.7%
5Y3.2%10Y3.2%0.0%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3%1.3%+1.0%
TTM2.5%1.4%+1.1%
YOY2.9%2.0%+0.9%
5Y3.2%2.1%+1.1%
10Y3.2%2.0%+1.2%
1.1.3. Return on Equity

Shows how efficient Bioteq is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bioteq to the Medical Instruments & Supplies industry mean.
  • 3.3% Return on Equity means Bioteq generated NT$0.03 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bioteque:

  • The MRQ is 3.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.3%TTM3.8%-0.5%
TTM3.8%YOY4.4%-0.6%
TTM3.8%5Y4.3%-0.6%
5Y4.3%10Y4.4%0.0%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3%2.6%+0.7%
TTM3.8%2.9%+0.9%
YOY4.4%3.9%+0.5%
5Y4.3%3.8%+0.5%
10Y4.4%3.9%+0.5%

1.2. Operating Efficiency of Bioteque.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Bioteq is operating .

  • Measures how much profit Bioteq makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bioteq to the Medical Instruments & Supplies industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bioteque:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY28.8%-28.8%
TTM-5Y25.7%-25.7%
5Y25.7%10Y26.0%-0.3%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-7.9%
TTM-7.5%-7.5%
YOY28.8%11.4%+17.4%
5Y25.7%10.2%+15.5%
10Y26.0%10.7%+15.3%
1.2.2. Operating Ratio

Measures how efficient Bioteq is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • An Operation Ratio of 1.24 means that the operating costs are NT$1.24 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of Bioteque:

  • The MRQ is 1.239. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.283. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.239TTM1.283-0.044
TTM1.283YOY1.291-0.008
TTM1.2835Y1.267+0.016
5Y1.26710Y1.266+0.001
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2391.133+0.106
TTM1.2831.124+0.159
YOY1.2911.105+0.186
5Y1.2671.097+0.170
10Y1.2661.056+0.210

1.3. Liquidity of Bioteque.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Bioteq is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A Current Ratio of 3.35 means the company has NT$3.35 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of Bioteque:

  • The MRQ is 3.351. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.835. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.351TTM2.835+0.516
TTM2.835YOY2.560+0.275
TTM2.8355Y3.585-0.750
5Y3.58510Y3.623-0.038
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3512.320+1.031
TTM2.8352.382+0.453
YOY2.5602.575-0.015
5Y3.5852.627+0.958
10Y3.6232.623+1.000
1.3.2. Quick Ratio

Measures if Bioteq is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bioteq to the Medical Instruments & Supplies industry mean.
  • A Quick Ratio of 0.63 means the company can pay off NT$0.63 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bioteque:

  • The MRQ is 0.628. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.621. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.628TTM0.621+0.006
TTM0.621YOY0.762-0.140
TTM0.6215Y0.938-0.317
5Y0.93810Y0.928+0.010
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6281.111-0.483
TTM0.6211.159-0.538
YOY0.7621.286-0.524
5Y0.9381.423-0.485
10Y0.9281.521-0.593

1.4. Solvency of Bioteque.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Bioteq assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bioteq to Medical Instruments & Supplies industry mean.
  • A Debt to Asset Ratio of 0.31 means that Bioteq assets are financed with 31.0% credit (debt) and the remaining percentage (100% - 31.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bioteque:

  • The MRQ is 0.310. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.339. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.310TTM0.339-0.030
TTM0.339YOY0.326+0.013
TTM0.3395Y0.269+0.070
5Y0.26910Y0.264+0.005
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3100.351-0.041
TTM0.3390.357-0.018
YOY0.3260.357-0.031
5Y0.2690.359-0.090
10Y0.2640.371-0.107
1.4.2. Debt to Equity Ratio

Measures if Bioteq is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bioteq to the Medical Instruments & Supplies industry mean.
  • A Debt to Equity ratio of 44.8% means that company has NT$0.45 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bioteque:

  • The MRQ is 0.448. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.517. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.448TTM0.517-0.068
TTM0.517YOY0.485+0.032
TTM0.5175Y0.378+0.139
5Y0.37810Y0.370+0.009
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4480.541-0.093
TTM0.5170.559-0.042
YOY0.4850.545-0.060
5Y0.3780.610-0.232
10Y0.3700.669-0.299

2. Market Valuation of Bioteque

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Bioteq generates.

  • Above 15 is considered overpriced but always compare Bioteq to the Medical Instruments & Supplies industry mean.
  • A PE ratio of 18.12 means the investor is paying NT$18.12 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bioteque:

  • The EOD is 20.423. Based on the earnings, the company is fair priced.
  • The MRQ is 18.118. Based on the earnings, the company is fair priced.
  • The TTM is 17.443. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD20.423MRQ18.118+2.306
MRQ18.118TTM17.443+0.675
TTM17.443YOY15.659+1.784
TTM17.4435Y18.031-0.587
5Y18.03110Y17.848+0.182
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD20.42315.252+5.171
MRQ18.11817.745+0.373
TTM17.44318.883-1.440
YOY15.65922.890-7.231
5Y18.03121.018-2.987
10Y17.84826.090-8.242
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bioteque:

  • The EOD is 9.588. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 8.505. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 17.589. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD9.588MRQ8.505+1.083
MRQ8.505TTM17.589-9.083
TTM17.589YOY-12.057+29.646
TTM17.5895Y65.134-47.545
5Y65.13410Y62.546+2.588
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD9.58810.158-0.570
MRQ8.50510.068-1.563
TTM17.5891.502+16.087
YOY-12.0574.281-16.338
5Y65.1347.622+57.512
10Y62.5460.247+62.299
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Bioteq is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A PB ratio of 2.39 means the investor is paying NT$2.39 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of Bioteque:

  • The EOD is 2.694. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.389. Based on the equity, the company is underpriced. +1
  • The TTM is 2.560. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.694MRQ2.389+0.304
MRQ2.389TTM2.560-0.171
TTM2.560YOY2.718-0.157
TTM2.5605Y3.076-0.515
5Y3.07610Y3.064+0.012
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD2.6942.434+0.260
MRQ2.3892.782-0.393
TTM2.5602.767-0.207
YOY2.7183.290-0.572
5Y3.0763.530-0.454
10Y3.0644.227-1.163
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Bioteque compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.3840.571+143%0.825+68%0.632+119%2.192-37%
Book Value Per Share--46.03543.395+6%41.014+12%39.213+17%38.936+18%
Current Ratio--3.3512.835+18%2.560+31%3.585-7%3.623-8%
Debt To Asset Ratio--0.3100.339-9%0.326-5%0.269+15%0.264+17%
Debt To Equity Ratio--0.4480.517-13%0.485-7%0.378+19%0.370+21%
Dividend Per Share----0%3.375-100%2.900-100%2.952-100%
Eps--1.5181.633-7%1.780-15%1.681-10%1.680-10%
Free Cash Flow Per Share--3.2332.187+48%-0.297+109%1.002+223%1.059+205%
Free Cash Flow To Equity Per Share--3.2332.187+48%-0.049+102%0.535+505%0.567+471%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--110.790--------
Intrinsic Value_10Y_min--92.725--------
Intrinsic Value_1Y_max--3.432--------
Intrinsic Value_1Y_min--3.367--------
Intrinsic Value_3Y_max--16.157--------
Intrinsic Value_3Y_min--15.307--------
Intrinsic Value_5Y_max--35.930--------
Intrinsic Value_5Y_min--32.846--------
Market Cap8592952000.000+11%7622780000.0007674753500.000-1%7709402500.000-1%8251659350.000-8%8170234200.000-7%
Net Profit Margin--0.2030.232-13%0.246-18%0.243-16%0.244-17%
Operating Margin----0%0.288-100%0.257-100%0.260-100%
Operating Ratio--1.2391.283-3%1.291-4%1.267-2%1.266-2%
Pb Ratio2.694+11%2.3892.560-7%2.718-12%3.076-22%3.064-22%
Pe Ratio20.423+11%18.11817.443+4%15.659+16%18.031+0%17.848+2%
Price Per Share124.000+11%110.000110.750-1%111.250-1%119.075-8%117.900-7%
Price To Free Cash Flow Ratio9.588+11%8.50517.589-52%-12.057+242%65.134-87%62.546-86%
Price To Total Gains Ratio89.594+11%79.47839.425+102%42.342+88%43.394+83%41.448+92%
Quick Ratio--0.6280.621+1%0.762-18%0.938-33%0.928-32%
Return On Assets--0.0230.025-9%0.029-22%0.032-28%0.032-29%
Return On Equity--0.0330.038-12%0.044-24%0.043-24%0.044-24%
Total Gains Per Share--1.3840.571+143%4.200-67%3.532-61%5.145-73%
Usd Book Value--98255911.60092621644.500+6%87539120.900+12%83696195.660+17%83104568.800+18%
Usd Book Value Change Per Share--0.0430.018+143%0.025+68%0.019+119%0.068-37%
Usd Book Value Per Share--1.4181.337+6%1.263+12%1.208+17%1.199+18%
Usd Dividend Per Share----0%0.104-100%0.089-100%0.091-100%
Usd Eps--0.0470.050-7%0.055-15%0.052-10%0.052-10%
Usd Free Cash Flow--6900894.0004668717.900+48%-633301.900+109%2139358.760+223%2259929.467+205%
Usd Free Cash Flow Per Share--0.1000.067+48%-0.009+109%0.031+223%0.033+205%
Usd Free Cash Flow To Equity Per Share--0.1000.067+48%-0.001+102%0.016+505%0.017+471%
Usd Market Cap264662921.600+11%234781624.000236382407.800-1%237449597.000-1%254151107.980-8%251643213.360-7%
Usd Price Per Share3.819+11%3.3883.411-1%3.427-1%3.668-8%3.631-7%
Usd Profit--3239698.0003484635.000-7%3800258.000-15%3588483.360-10%3586451.733-10%
Usd Revenue--15967243.60014974197.700+7%15479094.400+3%14764018.500+8%14673876.800+9%
Usd Total Gains Per Share--0.0430.018+143%0.129-67%0.109-61%0.158-73%
 EOD+4 -4MRQTTM+22 -10YOY+18 -175Y+16 -1910Y+14 -21

3.2. Fundamental Score

Let's check the fundamental score of Bioteque based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1520.423
Price to Book Ratio (EOD)Between0-12.694
Net Profit Margin (MRQ)Greater than00.203
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.628
Current Ratio (MRQ)Greater than13.351
Debt to Asset Ratio (MRQ)Less than10.310
Debt to Equity Ratio (MRQ)Less than10.448
Return on Equity (MRQ)Greater than0.150.033
Return on Assets (MRQ)Greater than0.050.023
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Bioteque based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.239
Ma 20Greater thanMa 50124.375
Ma 50Greater thanMa 100119.990
Ma 100Greater thanMa 200114.770
OpenGreater thanClose125.000
Total5/5 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Interest Income  -1,059869-190-669-859789-70554484



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets4,620,368
Total Liabilities1,430,241
Total Stockholder Equity3,190,127
 As reported
Total Liabilities 1,430,241
Total Stockholder Equity+ 3,190,127
Total Assets = 4,620,368

Assets

Total Assets4,620,368
Total Current Assets2,151,218
Long-term Assets2,469,150
Total Current Assets
Cash And Cash Equivalents 1,353,815
Short-term Investments 211,322
Net Receivables 191,678
Inventory 294,641
Other Current Assets 32,283
Total Current Assets  (as reported)2,151,218
Total Current Assets  (calculated)2,083,739
+/- 67,479
Long-term Assets
Property Plant Equipment 2,453,900
Long-term Assets Other 4,991
Long-term Assets  (as reported)2,469,150
Long-term Assets  (calculated)2,458,891
+/- 10,259

Liabilities & Shareholders' Equity

Total Current Liabilities642,057
Long-term Liabilities788,184
Total Stockholder Equity3,190,127
Total Current Liabilities
Short Long Term Debt 147,674
Accounts payable 136,801
Other Current Liabilities 5,124
Total Current Liabilities  (as reported)642,057
Total Current Liabilities  (calculated)289,599
+/- 352,458
Long-term Liabilities
Long term Debt 446,230
Capital Lease Obligations Min Short Term Debt300,837
Long-term Liabilities  (as reported)788,184
Long-term Liabilities  (calculated)747,067
+/- 41,117
Total Stockholder Equity
Retained Earnings 1,657,141
Total Stockholder Equity (as reported)3,190,127
Total Stockholder Equity (calculated)1,657,141
+/- 1,532,986
Other
Capital Stock692,983
Common Stock Shares Outstanding 69,298
Net Invested Capital 3,784,031
Net Working Capital 1,509,161
Property Plant and Equipment Gross 3,745,505



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
> Total Assets 
2,771,542
2,922,887
3,096,679
2,948,965
2,940,498
3,077,740
3,239,741
3,357,587
3,563,757
3,701,963
3,841,651
3,636,403
3,860,855
3,981,484
4,126,944
4,278,740
4,480,494
4,510,269
4,581,387
4,495,188
4,620,368
4,620,3684,495,1884,581,3874,510,2694,480,4944,278,7404,126,9443,981,4843,860,8553,636,4033,841,6513,701,9633,563,7573,357,5873,239,7413,077,7402,940,4982,948,9653,096,6792,922,8872,771,542
   > Total Current Assets 
1,690,994
1,827,726
1,984,598
1,830,834
1,815,829
1,961,059
2,128,216
1,942,207
2,070,745
2,225,208
2,180,544
1,908,079
1,946,590
1,866,847
1,808,384
1,698,912
1,917,790
1,980,983
2,070,603
1,989,187
2,151,218
2,151,2181,989,1872,070,6031,980,9831,917,7901,698,9121,808,3841,866,8471,946,5901,908,0792,180,5442,225,2082,070,7451,942,2072,128,2161,961,0591,815,8291,830,8341,984,5981,827,7261,690,994
       Cash And Cash Equivalents 
926,601
1,065,930
1,175,933
1,000,069
1,054,596
1,147,953
1,351,293
1,177,059
1,193,574
1,331,030
1,282,772
918,068
872,610
879,955
890,331
771,651
1,017,296
1,119,033
1,183,710
1,092,287
1,353,815
1,353,8151,092,2871,183,7101,119,0331,017,296771,651890,331879,955872,610918,0681,282,7721,331,0301,193,5741,177,0591,351,2931,147,9531,054,5961,000,0691,175,9331,065,930926,601
       Short-term Investments 
1,342
178,836
180,027
199,620
178,631
177,859
178,353
177,194
292,596
293,026
298,297
386,285
439,503
279,097
187,945
189,043
250,262
250,356
258,725
270,943
211,322
211,322270,943258,725250,356250,262189,043187,945279,097439,503386,285298,297293,026292,596177,194178,353177,859178,631199,620180,027178,8361,342
       Net Receivables 
282,676
204,898
243,800
249,000
287,792
325,875
312,198
292,977
293,146
286,933
270,946
255,999
287,417
331,004
324,434
327,620
290,930
189,650
217,545
210,650
191,678
191,678210,650217,545189,650290,930327,620324,434331,004287,417255,999270,946286,933293,146292,977312,198325,875287,792249,000243,800204,898282,676
       Inventory 
281,734
279,312
288,139
281,010
268,278
283,047
260,707
255,895
265,147
295,652
301,848
306,841
314,914
338,521
354,247
350,774
331,713
328,635
298,602
293,917
294,641
294,641293,917298,602328,635331,713350,774354,247338,521314,914306,841301,848295,652265,147255,895260,707283,047268,278281,010288,139279,312281,734
       Other Current Assets 
51,894
28,155
29,099
33,248
57,031
57,790
56,699
68,783
55,363
47,698
55,142
69,327
60,417
67,491
81,738
92,165
28,190
29,863
35,842
52,742
32,283
32,28352,74235,84229,86328,19092,16581,73867,49160,41769,32755,14247,69855,36368,78356,69957,79057,03133,24829,09928,15551,894
   > Long-term Assets 
0
1,095,161
1,112,081
1,118,131
1,124,669
1,116,681
1,111,525
1,415,380
1,493,012
1,476,755
1,661,107
1,728,324
1,914,265
2,114,637
2,318,560
2,579,828
2,562,704
2,529,286
2,510,784
2,506,001
2,469,150
2,469,1502,506,0012,510,7842,529,2862,562,7042,579,8282,318,5602,114,6371,914,2651,728,3241,661,1071,476,7551,493,0121,415,3801,111,5251,116,6811,124,6691,118,1311,112,0811,095,1610
       Property Plant Equipment 
944,734
1,010,715
1,011,631
1,002,304
1,008,147
1,011,223
999,202
1,365,462
1,449,970
1,443,286
1,629,955
1,688,175
1,843,945
1,959,475
2,064,282
2,568,786
2,550,836
2,517,687
2,499,908
2,494,829
2,453,900
2,453,9002,494,8292,499,9082,517,6872,550,8362,568,7862,064,2821,959,4751,843,9451,688,1751,629,9551,443,2861,449,9701,365,462999,2021,011,2231,008,1471,002,3041,011,6311,010,715944,734
       Long Term Investments 
2,209
2,221
2,026
2,035
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000002,0352,0262,2212,209
       Long-term Assets Other 
0
3,969
3,952
6,044
7,137
6,940
5,841
5,362
5,539
5,830
5,513
4,678
4,398
4,579
4,094
4,234
5,647
5,403
4,640
4,622
4,991
4,9914,6224,6405,4035,6474,2344,0944,5794,3984,6785,5135,8305,5395,3625,8416,9407,1376,0443,9523,9690
> Total Liabilities 
457,515
491,128
805,396
545,081
452,371
477,819
822,297
828,987
899,549
916,428
978,943
962,372
1,057,678
1,352,209
1,356,544
1,341,684
1,448,508
1,694,968
1,652,247
1,400,971
1,430,241
1,430,2411,400,9711,652,2471,694,9681,448,5081,341,6841,356,5441,352,2091,057,678962,372978,943916,428899,549828,987822,297477,819452,371545,081805,396491,128457,515
   > Total Current Liabilities 
385,648
409,984
730,738
471,664
364,977
387,238
723,336
426,270
423,858
443,430
507,421
470,139
595,251
894,369
908,642
602,568
573,734
841,606
838,902
628,032
642,057
642,057628,032838,902841,606573,734602,568908,642894,369595,251470,139507,421443,430423,858426,270723,336387,238364,977471,664730,738409,984385,648
       Short-term Debt 
35,840
67,466
130,150
118,698
51,442
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000051,442118,698130,15067,46635,840
       Short Long Term Debt 
35,840
67,466
130,150
118,698
51,442
37,780
120,871
120,684
59,119
95,577
95,513
35,633
45,317
25,135
37,419
36,568
34,288
43,830
104,021
175,068
147,674
147,674175,068104,02143,83034,28836,56837,41925,13545,31735,63395,51395,57759,119120,684120,87137,78051,442118,698130,15067,46635,840
       Accounts payable 
113,063
78,507
89,558
74,484
107,856
116,953
126,979
126,435
143,845
126,912
130,620
129,826
159,013
138,054
129,710
124,587
135,486
94,358
84,339
105,177
136,801
136,801105,17784,33994,358135,486124,587129,710138,054159,013129,826130,620126,912143,845126,435126,979116,953107,85674,48489,55878,507113,063
       Other Current Liabilities 
175,524
8,916
9,760
22,714
242,161
258,712
515,588
213,374
266,361
245,534
307,137
290,781
379,210
718,384
731,875
428,355
389,740
7,757
10,121
15,029
5,124
5,12415,02910,1217,757389,740428,355731,875718,384379,210290,781307,137245,534266,361213,374515,588258,712242,16122,7149,7608,916175,524
   > Long-term Liabilities 
0
81,144
74,658
73,417
87,394
90,581
98,961
402,717
475,691
472,998
471,522
492,233
462,427
457,840
447,902
739,116
874,774
853,362
813,345
772,939
788,184
788,184772,939813,345853,362874,774739,116447,902457,840462,427492,233471,522472,998475,691402,71798,96190,58187,39473,41774,65881,1440
       Capital Lease Obligations 
0
19,130
17,935
16,707
15,482
20,271
28,810
339,583
336,122
333,701
330,205
326,692
323,206
324,817
321,280
318,804
315,234
310,436
307,243
304,046
300,837
300,837304,046307,243310,436315,234318,804321,280324,817323,206326,692330,205333,701336,122339,58328,81020,27115,48216,70717,93519,1300
       Long-term Liabilities Other 
0
8
0
0
0
0
0
0
87,700
87,700
87,700
0
0
0
0
0
0
0
0
0
0
000000000087,70087,70087,70000000080
> Total Stockholder Equity
2,314,027
2,431,759
2,291,283
2,403,884
2,488,127
2,599,921
2,417,444
2,528,600
2,664,208
2,785,535
2,862,708
2,674,031
2,803,177
2,629,275
2,770,400
2,937,056
3,031,986
2,815,301
2,929,140
3,094,217
3,190,127
3,190,1273,094,2172,929,1402,815,3013,031,9862,937,0562,770,4002,629,2752,803,1772,674,0312,862,7082,785,5352,664,2082,528,6002,417,4442,599,9212,488,1272,403,8842,291,2832,431,7592,314,027
   Common Stock
692,983
692,983
692,983
692,983
692,983
692,983
692,983
692,983
692,983
692,983
692,983
692,983
692,983
692,983
692,983
692,983
692,983
0
0
0
0
0000692,983692,983692,983692,983692,983692,983692,983692,983692,983692,983692,983692,983692,983692,983692,983692,983692,983
   Retained Earnings 
1,294,932
1,121,066
939,999
1,053,705
1,481,690
1,590,235
1,421,141
1,542,570
1,690,032
1,810,538
1,901,221
1,713,473
1,845,646
1,655,889
1,780,008
1,913,864
2,024,937
1,299,018
1,402,009
1,548,089
1,657,141
1,657,1411,548,0891,402,0091,299,0182,024,9371,913,8641,780,0081,655,8891,845,6461,713,4731,901,2211,810,5381,690,0321,542,5701,421,1411,590,2351,481,6901,053,705939,9991,121,0661,294,932
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
10,944
12,679
19,230
18,125
-1,714
1,535
-11,848
-22,121
-33,975
-33,154
-46,664
-47,593
-50,620
-34,765
-17,759
15,041
-1,102
-4,643
0
0
0
000-4,643-1,10215,041-17,759-34,765-50,620-47,593-46,664-33,154-33,975-22,121-11,8481,535-1,71418,12519,23012,67910,944



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,944,701
Cost of Revenue-1,125,764
Gross Profit818,937818,937
 
Operating Income (+$)
Gross Profit818,937
Operating Expense-1,364,525
Operating Income580,176-545,588
 
Operating Expense (+$)
Research Development70,442
Selling General Administrative168,319
Selling And Marketing Expenses0
Operating Expense1,364,525238,761
 
Net Interest Income (+$)
Interest Income10,968
Interest Expense-11,603
Other Finance Cost-0
Net Interest Income-635
 
Pretax Income (+$)
Operating Income580,176
Net Interest Income-635
Other Non-Operating Income Expenses0
Income Before Tax (EBT)569,515580,176
EBIT - interestExpense = -11,603
452,550
464,153
Interest Expense11,603
Earnings Before Interest and Taxes (EBIT)0581,118
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax569,515
Tax Provision-116,965
Net Income From Continuing Ops452,550452,550
Net Income452,550
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0635
 

Technical Analysis of Bioteq
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bioteq. The general trend of Bioteq is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bioteq's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Bioteque.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 127.50 < 127.50.

The bearish price targets are: 121.50 > 116.60 > 115.50.

Tweet this
Bioteque Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Bioteque. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Bioteque Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Bioteque. The current macd is 1.22323747.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bioteq price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Bioteq. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Bioteq price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Bioteque Daily Moving Average Convergence/Divergence (MACD) ChartBioteque Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Bioteque. The current adx is 30.51.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Bioteq shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Bioteque Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Bioteque. The current sar is 120.16.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Bioteque Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Bioteque. The current rsi is 52.24. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Bioteque Daily Relative Strength Index (RSI) ChartBioteque Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Bioteque. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -3/(-6 +6).

  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bioteq price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Bioteque Daily Stochastic Oscillator ChartBioteque Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Bioteque. The current cci is -26.41509434.

Bioteque Daily Commodity Channel Index (CCI) ChartBioteque Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Bioteque. The current cmo is -1.50171481.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Bioteque Daily Chande Momentum Oscillator (CMO) ChartBioteque Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Bioteque. The current willr is -50.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Bioteq is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Bioteque Daily Williams %R ChartBioteque Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Bioteque.

Bioteque Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Bioteque. The current atr is 2.49467087.

Bioteque Daily Average True Range (ATR) ChartBioteque Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Bioteque. The current obv is 6,936,797.

Bioteque Daily On-Balance Volume (OBV) ChartBioteque Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Bioteque. The current mfi is 42.67.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Bioteque Daily Money Flow Index (MFI) ChartBioteque Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Bioteque.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Bioteque Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Bioteque based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.239
Ma 20Greater thanMa 50124.375
Ma 50Greater thanMa 100119.990
Ma 100Greater thanMa 200114.770
OpenGreater thanClose125.000
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Bioteq with someone you think should read this too:
  • Are you bullish or bearish on Bioteq? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bioteq? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Bioteque

I send you an email if I find something interesting about Bioteque.


Comments

How you think about this?

Leave a comment

Stay informed about Bioteque.

Receive notifications about Bioteque in your mailbox!